Literature DB >> 21420160

Reshaping the Bet v 1 fold modulates T(H) polarization.

Michael Wallner1, Michael Hauser, Martin Himly, Nadja Zaborsky, Sonja Mutschlechner, Andrea Harrer, Claudia Asam, Ulrike Pichler, Ronald van Ree, Peter Briza, Josef Thalhamer, Barbara Bohle, Gernot Achatz, Fatima Ferreira.   

Abstract

BACKGROUND: Several alternative mechanisms have been proposed to explain why some proteins are able to induce a T(H)2-biased and IgE-mediated immune response. These include specific interactions with receptors of the innate immune system, proteolytic activities, allergen-associated carbohydrate structures, and intrinsic structural determinants.
OBJECTIVES: Available data suggest that a fold-dependent allergy-promoting mechanism could be a driving force for the T(H)2-polarization activity of Bet v 1, the major birch pollen allergen.
METHODS: Computer-aided sequence and fold analysis of the Bet v 1 family identified a short stretch susceptible for mutations inducing an altered fold of the entire molecule. With this knowledge, 7 consecutive amino acids of Bet v 1 were replaced with the homologous Mal d 1 sequence, creating the derivative BM4.
RESULTS: The minimal changes of the sequence led to a loss of the Bet v 1-like fold and influenced the immunologic behavior. Compared to wild-type Bet v 1, BM4 induced elevated T-cell proliferation of human PBMCs. In the mouse model, immunization with Bet v 1 absorbed to aluminum hydroxide triggered strong T(H)2 polarization, whereas BM4 immunization additionally recruited T(H)1 cells. Furthermore, the fold variant BM4 showed enhanced uptake by dendritic cells and a decreased susceptibility to endo-/lysosomal proteolysis.
CONCLUSION: Modifications in the 3-dimensional structure of Bet v 1.0101 resulted in a change of its immunologic properties. We observed that the fold alteration led to a modified crosstalk with dendritic cells and a shift of the immune response polarization toward a mixed T(H)1/T(H)2 cytokine production.
Copyright © 2011 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21420160      PMCID: PMC5689381          DOI: 10.1016/j.jaci.2011.01.064

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  27 in total

1.  Cross-reactivity and epitope analysis of Pru a 1, the major cherry allergen.

Authors:  S Scheurer; D Y Son; M Boehm; F Karamloo; S Franke; A Hoffmann; D Haustein; S Vieths
Journal:  Mol Immunol       Date:  1999-02       Impact factor: 4.407

2.  Development of a functional in vitro assay as a novel tool for the standardization of allergen extracts in the human system.

Authors:  L Vogel; D Lüttkopf; L Hatahet; D Haustein; S Vieths
Journal:  Allergy       Date:  2005-08       Impact factor: 13.146

Review 3.  The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification.

Authors:  R van Ree; M D Chapman; F Ferreira; S Vieths; D Bryan; O Cromwell; M Villalba; S R Durham; W M Becker; M Aalbers; C André; D Barber; A Cistero Bahima; A Custovic; A Didierlaurent; C Dolman; J W Dorpema; G Di Felice; F Eberhardt; E Fernandez Caldas; M Fernandez Rivas; H Fiebig; M Focke; K Fötisch; G Gadermaier; R G Das; E Gonzalez Mancebo; M Himly; T Kinaciyan; A C Knulst; A M Kroon; U Lepp; F M Marco; A Mari; P Moingeon; R Monsalve; A Neubauer; S Notten; P Ooievaar-de Heer; G Pauli; C Pini; A Purohit; J Quiralte; S Rak; M Raulf-Heimsoth; M M San Miguel Moncin; B Simpson; A Tsay; L Vailes; M Wallner; B Weber
Journal:  Allergy       Date:  2008-03       Impact factor: 13.146

4.  Standardization of allergen products: 1. Detailed characterization of GMP-produced recombinant Bet v 1.0101 as biological reference preparation.

Authors:  M Himly; E Nony; H Chabre; L Van Overtvelt; A Neubauer; R van Ree; K-H Buchheit; S Vieths; P Moingeon; F Ferreira
Journal:  Allergy       Date:  2009-01-31       Impact factor: 13.146

5.  Designing hypoallergenic derivatives for allergy treatment by means of in silico mutation and screening.

Authors:  Theresa Thalhamer; Heidi Dobias; Tatjana Stepanoska; Martina Pröll; Hanno Stutz; Oliver Dissertori; Peter Lackner; Fatima Ferreira; Michael Wallner; Josef Thalhamer; Arnulf Hartl
Journal:  J Allergy Clin Immunol       Date:  2010-04       Impact factor: 10.793

6.  The major birch allergen, Bet v 1, shows affinity for a broad spectrum of physiological ligands.

Authors:  Jesper E Mogensen; Reinhard Wimmer; Jørgen N Larsen; Michael D Spangfort; Daniel E Otzen
Journal:  J Biol Chem       Date:  2002-04-12       Impact factor: 5.157

Review 7.  Transition from a botanical to a molecular classification in tree pollen allergy: implications for diagnosis and therapy.

Authors:  Nadine Mothes; Friedrich Horak; Rudolf Valenta
Journal:  Int Arch Allergy Immunol       Date:  2004-11-30       Impact factor: 2.749

8.  Extent of T cell receptor ligation can determine the functional differentiation of naive CD4+ T cells.

Authors:  S Constant; C Pfeiffer; A Woodard; T Pasqualini; K Bottomly
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

9.  Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy.

Authors:  F Ferreira; K Hirtenlehner; A Jilek; J Godnik-Cvar; H Breiteneder; R Grimm; K Hoffmann-Sommergruber; O Scheiner; D Kraft; M Breitenbach; H J Rheinberger; C Ebner
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

Review 10.  Development of recombinant allergens for diagnosis and therapy.

Authors:  Matthias Egger; Michael Hauser; Martin Himly; Nicole Wopfner; Michael Wallner; Fatima Ferreira
Journal:  Front Biosci (Elite Ed)       Date:  2009-06-01
View more
  27 in total

1.  Antigenic Determinants of the Bilobal Cockroach Allergen Bla g 2.

Authors:  Judith A Woodfolk; Jill Glesner; Paul W Wright; Christopher L Kepley; Mi Li; Martin Himly; Lyndsey M Muehling; Alla Gustchina; Alexander Wlodawer; Martin D Chapman; Anna Pomés
Journal:  J Biol Chem       Date:  2015-12-07       Impact factor: 5.157

Review 2.  A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs.

Authors:  Karl-Josef Kallen; Andreas Theß
Journal:  Ther Adv Vaccines       Date:  2014-01

Review 3.  100 Years later: Celebrating the contributions of x-ray crystallography to allergy and clinical immunology.

Authors:  Anna Pomés; Maksymilian Chruszcz; Alla Gustchina; Wladek Minor; Geoffrey A Mueller; Lars C Pedersen; Alexander Wlodawer; Martin D Chapman
Journal:  J Allergy Clin Immunol       Date:  2015-07       Impact factor: 10.793

4.  Expression and Characterization of Functional Recombinant Bet v 1.0101 in the Chloroplast of Chlamydomonas reinhardtii.

Authors:  Sonja Hirschl; Claudia Ralser; Claudia Asam; Alessandro Gangitano; Sara Huber; Christof Ebner; Barbara Bohle; Martin Wolf; Peter Briza; Fatima Ferreira; Christoph Griesbeck; Michael Wallner
Journal:  Int Arch Allergy Immunol       Date:  2017-05-12       Impact factor: 2.749

Review 5.  Recombinant Allergens in Structural Biology, Diagnosis, and Immunotherapy.

Authors:  Angelika Tscheppe; Heimo Breiteneder
Journal:  Int Arch Allergy Immunol       Date:  2017-05-04       Impact factor: 2.749

6.  Are allergens more abundant and/or more stable than other proteins in pollens and dust?

Authors:  Aurora Cabrera; Thomas A Randall; Ryenne N Ogburn; Betelihem Mebrahtu; Julia H R Johnson; Alexander C Y Foo; Michael C Fitzgerald; Geoffrey A Mueller
Journal:  Allergy       Date:  2019-12-10       Impact factor: 13.146

Review 7.  Contributions and Future Directions for Structural Biology in the Study of Allergens.

Authors:  Geoffrey A Mueller
Journal:  Int Arch Allergy Immunol       Date:  2017-10-10       Impact factor: 2.749

Review 8.  Vaccines for allergy.

Authors:  Birgit Linhart; Rudolf Valenta
Journal:  Curr Opin Immunol       Date:  2012-04-20       Impact factor: 7.486

9.  Folded or Not? Tracking Bet v 1 Conformation in Recombinant Allergen Preparations.

Authors:  Felix Husslik; Kay-Martin Hanschmann; Ariane Krämer; Christian Seutter von Loetzen; Kristian Schweimer; Iris Bellinghausen; Regina Treudler; Jan C Simon; Lothar Vogel; Elke Völker; Stefanie Randow; Andreas Reuter; Paul Rösch; Stefan Vieths; Thomas Holzhauser; Dirk Schiller
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

10.  The fold variant BM4 is beneficial in a therapeutic Bet v 1 mouse model.

Authors:  Ulrike Pichler; Claudia Asam; Richard Weiss; Almedina Isakovic; Michael Hauser; Peter Briza; Fatima Ferreira; Michael Wallner
Journal:  Biomed Res Int       Date:  2013-09-23       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.